Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 13, 2021
Principal Executive Office: Boca Raton, FL
Trading Symbol: TXMD (Nasdaq)
This filing reports the entry into a material definitive agreement regarding the company's financing structure and the furnishing of an investor presentation.
Key Financial Metrics and Agreements
Debt and Financing Amendments:
- Amendment No. 7 to Financing Agreement: Entered into on January 13, 2021, modifying the agreement dated April 24, 2019.
- Amendment Fee: The Company paid the Administrative Agent a fee of $5 million in connection with this amendment.
- Revenue Covenants: Minimum consolidated net revenue requirements for commercial sales of IMVEXXY, BIJUVA, and ANNOVERA were reduced for the following periods:
- Fiscal Quarter ending March 31, 2021: Reduced to $18 million.
- Fiscal Quarter ending June 30, 2021: Reduced to $22 million.
Warrant Adjustments:
- Lender Warrants Second Amendment: Warrants issued to the Administrative Agent and lenders were amended to include an additional adjustment to the exercise price if the Company conducts certain dilutive issuances prior to March 31, 2021.
Other Metrics: The filing text does not provide specific values for current revenue, profit, cash flow, margins, or total debt outstanding as of the report date.
Material Changes Versus Prior Period
The primary material change is the reduction of minimum consolidated net revenue requirements for the first two quarters of fiscal year 2021 compared to the previous terms of the Financing Agreement. Additionally, the exercise price mechanics for Lender Warrants were modified to account for potential dilutive issuances.
Guidance, Outlook, and Risks
Management Commentary and Disclosure:
- The Company furnished an investor presentation (Exhibit 99.1) dated January 13, 2021, which may be used in meetings with investors or analysts.
- Information in the investor presentation is furnished pursuant to Regulation FD and is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934.
Risks and Contingencies:
- The summary of Amendment No. 7 and the Lender Warrants Second Amendment is not complete and is subject to the full text of the agreements, which will be filed in the Form 10-Q for the quarter ending March 31, 2021.
- The Company faces potential dilution if certain issuances occur prior to March 31, 2021, triggering warrant exercise price adjustments.
Important Facts for Investor Verification
- Verify the full text of Amendment No. 7 and the Lender Warrants Second Amendment in the upcoming Form 10-Q for the quarter ending March 31, 2021.
- Confirm the impact of the $5 million amendment fee on the Company's immediate liquidity position.
- Review the investor presentation (Exhibit 99.1) for updated operational guidance, noting it is not a formal filing.
- Monitor the Company's commercial sales performance against the new reduced revenue covenants of $18 million (Q1 2021) and $22 million (Q2 2021).